Join
Live feed
·
PRReleasevia Quantisnow
Adlai Nortye Ltd. logo

Adlai Nortye Announces First Patient Enrolled in Global Phase 1 Trial of Pan-RAS (ON) Inhibitor AN9025 for Solid Tumors Harboring RAS Mutations

ByQuantisnow·Wall Street's wire, on your screen.
ANL· Adlai Nortye Ltd.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ANL (Adlai Nortye Ltd.) and more on Quantisnow.